| 1 |
34596822 | Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer. | 2022 Apr |
1 |
| 2 |
35190641 | p53-NEIL1 co-abnormalities induce genomic instability and promote synthetic lethality with Chk1 inhibition in multiple myeloma having concomitant 17p13(del) and 1q21(gain). | 2022 Apr |
1 |
| 3 |
35418303 | Clinically relevant CHK1 inhibitors abrogate wild-type and Y537S mutant ERĪ± expression and proliferation in luminal primary and metastatic breast cancer cells. | 2022 Apr 13 |
2 |
| 4 |
35430566 | SLFN12 Over-expression Sensitizes Triple Negative Breast Cancer Cells to Chemotherapy Drugs and Radiotherapy. | 2022 May-Jun |
1 |
| 5 |
34081985 | Checkpoint kinases are required for oocyte meiotic progression by the maintenance of normal spindle structure and chromosome condensation. | 2021 Aug 15 |
3 |
| 6 |
34314706 | One therapeutic approach for triple-negative breast cancer: Checkpoint kinase 1 inhibitor AZD7762 combination with neoadjuvant carboplatin. | 2021 Oct 5 |
2 |
| 7 |
34572942 | RAD50 Loss of Function Variants in the Zinc Hook Domain Associated with Higher Risk of Familial Esophageal Squamous Cell Carcinoma. | 2021 Sep 21 |
1 |
| 8 |
32857208 | Radiosensitization of NSCLC cells to X-rays and carbon ions by the CHK1/CHK2 inhibitor AZD7762, Honokiol and Tunicamycin. | 2020 Nov |
2 |
| 9 |
30633885 | Acetyl-macrocalin B suppresses tumor growth in esophageal squamous cell carcinoma and exhibits synergistic anti-cancer effects with the Chk1/2 inhibitor AZD7762. | 2019 Feb 15 |
2 |
| 10 |
30771522 | Checkpoint Kinase 1 Inhibition Enhances Cisplatin Cytotoxicity and Overcomes Cisplatin Resistance in SCLC by Promoting Mitotic Cell Death. | 2019 Jun |
1 |
| 11 |
31372095 | Checkpoint kinase inhibitor AZD7762 enhance cisplatin-induced apoptosis in osteosarcoma cells. | 2019 |
2 |
| 12 |
29149649 | Chk1 inhibitors overcome imatinib resistance in chronic myeloid leukemia cells. | 2018 Jan |
1 |
| 13 |
29301085 | Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors. | 2018 Feb 8 |
1 |
| 14 |
29704517 | DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer. | 2018 Aug 1 |
1 |
| 15 |
28030798 | Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading. | 2017 Feb 14 |
1 |
| 16 |
28049532 | Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine. | 2017 Jan 3 |
3 |
| 17 |
28228262 | Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. | 2017 Feb 21 |
4 |
| 18 |
28376202 | Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma. | 2017 Mar 1 |
1 |
| 19 |
26748709 | Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. | 2016 Jan 12 |
1 |
| 20 |
26890478 | Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry. | 2016 |
1 |
| 21 |
27167194 | Targeting radioresistant breast cancer cells by single agent CHK1 inhibitor via enhancing replication stress. | 2016 Jun 7 |
1 |
| 22 |
27272773 | Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines. | 2016 Jun |
1 |
| 23 |
27449089 | Checkpoint kinase 1 expression is an adverse prognostic marker and therapeutic target in MYC-driven medulloblastoma. | 2016 Aug 16 |
1 |
| 24 |
25880358 | Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma. | 2015 Apr 9 |
1 |
| 25 |
26025928 | Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells. | 2015 Aug 28 |
1 |
| 26 |
26054341 | Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. | 2015 Jun 10 |
1 |
| 27 |
26439697 | Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. | 2015 Nov 10 |
1 |
| 28 |
24362713 | Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary. | 2014 Jan |
1 |
| 29 |
24418519 | Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer. | 2014 Mar |
5 |
| 30 |
24448638 | Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. | 2014 Mar |
1 |
| 31 |
24804719 | Piperine causes G1 phase cell cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation. | 2014 |
2 |
| 32 |
25104095 | Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. | 2014 Aug 7 |
1 |
| 33 |
25301733 | Pharmacological targeting the ATR-CHK1-WEE1 axis involves balancing cell growth stimulation and apoptosis. | 2014 Nov 15 |
1 |
| 34 |
23483975 | A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. | 2013 |
2 |
| 35 |
23544166 | DW-MRI as a Predictive Biomarker of Radiosensitization of GBM through Targeted Inhibition of Checkpoint Kinases. | 2013 Apr |
1 |
| 36 |
23892959 | Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. | 2013 Sep |
1 |
| 37 |
23917378 | PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. | 2013 May |
1 |
| 38 |
24349411 | Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers. | 2013 |
1 |
| 39 |
22117197 | Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. | 2012 May |
1 |
| 40 |
22189968 | Potentiation of the novel topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor AZD7762. | 2012 Feb 15 |
3 |
| 41 |
22258035 | Evaluation of checkpoint kinase targeting therapy in acute myeloid leukemia with complex karyotype. | 2012 Mar |
1 |
| 42 |
22313687 | Enhancing CHK1 inhibitor lethality in glioblastoma. | 2012 Apr |
1 |
| 43 |
22653969 | The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. | 2012 Aug |
2 |
| 44 |
22825736 | The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. | 2012 Oct |
3 |
| 45 |
21154747 | Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma. | 2011 Oct 15 |
1 |
| 46 |
21291864 | Inhibition of checkpoint kinase 1 sensitizes lung cancer brain metastases to radiotherapy. | 2011 Mar 4 |
1 |
| 47 |
21482692 | Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. | 2011 Jun 1 |
4 |
| 48 |
21642769 | Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. | 2011 Aug 1 |
1 |
| 49 |
21911831 | Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2. | 2011 Nov 10 |
1 |
| 50 |
22106282 | Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors. | 2011 Dec 6 |
2 |